34,701 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Bender Robert & Associates

Bender Robert & Associates bought a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 34,701 shares of the company’s stock, valued at approximately $370,000.

A number of other large investors also recently modified their holdings of the business. BNP Paribas Financial Markets grew its position in UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after buying an additional 5,890 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in UroGen Pharma during the fourth quarter worth approximately $126,000. Intech Investment Management LLC bought a new position in UroGen Pharma during the 3rd quarter valued at $155,000. Verition Fund Management LLC acquired a new position in shares of UroGen Pharma during the 3rd quarter valued at $168,000. Finally, SG Americas Securities LLC lifted its holdings in shares of UroGen Pharma by 44.1% in the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock valued at $216,000 after buying an additional 6,207 shares during the period. 91.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares of the company’s stock, valued at $294,853.52. The trade was a 21.80 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by corporate insiders.

UroGen Pharma Stock Performance

UroGen Pharma stock opened at $10.82 on Wednesday. UroGen Pharma Ltd. has a fifty-two week low of $9.03 and a fifty-two week high of $20.70. The firm’s 50 day simple moving average is $10.45 and its 200-day simple moving average is $11.70. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The company has a market cap of $253.77 million, a P/E ratio of -3.43 and a beta of 1.12.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The business had revenue of $24.57 million for the quarter, compared to analysts’ expectations of $25.25 million. As a group, equities research analysts predict that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on URGN. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Monday. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price for the company. Finally, HC Wainwright dropped their price target on UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, UroGen Pharma has an average rating of “Buy” and a consensus price target of $38.20.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.